Sanofi Reports Encouraging Results From Phase 2b Study With BTK Inhibitor Kumar Jeetendra | April 23, 2020 Sanofi said its investigational Bruton’s tyrosine kinase inhibitor, an oral, mind penetrant, particular little particle accomplished both the essential and auxiliary endpoints in a Phase 2b preliminary assessing viability and security in members with backsliding types of various sclerosis. In the investigation, essential and optional goals were met with 85% or more noteworthy relative decrease …
